HbA and biomarkers of diabetes mellitus in : ten years after.
Fiche publication
Date publication
octobre 2022
Journal
Clinical chemistry and laboratory medicine
Lien Pubmed
Résumé
Since its discovery in the late 1960s, HbA has proven to be a major biomarker of diabetes mellitus survey and diagnosis. Other biomarkers have also been described using classical laboratory methods or more innovative, non-invasive ones. All biomarkers of diabetes, including the historical glucose assay, have well-controlled strengths and limitations, determining their indications in clinical use. They all request high quality preanalytical and analytical methodologies, necessitating a strict evaluation of their performances by external quality control assessment trials. Specific requirements are needed for point-of-care testing technologies. This general overview, which describes how old and new tools of diabetes mellitus biological survey have evolved over the last decade, has been built through the prism of papers published in during this period.
Mots clés
Clinical Chemistry and Laboratory Medicine , HbA1c, biomarkers, diabetes mellitus, glycation, point-of-care testing
Référence
Clin Chem Lab Med. 2022 10 14;: